240 related articles for article (PubMed ID: 24626184)
1. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV
Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
[TBL] [Abstract][Full Text] [Related]
3. The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer.
Moore HC; Jordan LB; Bray SE; Baker L; Quinlan PR; Purdie CA; Thompson AM; Bourdon JC; Fuller-Pace FV
Oncogene; 2010 Dec; 29(49):6475-84. PubMed ID: 20818423
[TBL] [Abstract][Full Text] [Related]
4. p53-dependent repression of polo-like kinase-1 (PLK1).
McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
[TBL] [Abstract][Full Text] [Related]
5. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
6. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the RNA helicase p68 (Ddx5) as a transcriptional regulator.
Nicol SM; Fuller-Pace FV
Methods Mol Biol; 2010; 587():265-79. PubMed ID: 20225156
[TBL] [Abstract][Full Text] [Related]
8. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of
Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y
Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081
[No Abstract] [Full Text] [Related]
9. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
10. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
11. Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1).
Chang YC; Wu CH; Yen TC; Ouyang P
J Biol Chem; 2012 Feb; 287(6):4376-85. PubMed ID: 22184120
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
13. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
14. Molecular interactions of polo-like kinase 1 in human cancers.
Weng Ng WT; Shin JS; Roberts TL; Wang B; Lee CS
J Clin Pathol; 2016 Jul; 69(7):557-62. PubMed ID: 26941182
[TBL] [Abstract][Full Text] [Related]
15. Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.
Louwen F; Yuan J
Oncotarget; 2013 Jul; 4(7):958-71. PubMed ID: 23948487
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of p68 RNA Helicase (DDX5) Activates a Survival Pathway Involving mTOR and MDM2 Signals.
Kokolo M; Bach-Elias M
Folia Biol (Praha); 2017; 63(2):52-59. PubMed ID: 28557706
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
[TBL] [Abstract][Full Text] [Related]
18. The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer.
Hashemi V; Masjedi A; Hazhir-Karzar B; Tanomand A; Shotorbani SS; Hojjat-Farsangi M; Ghalamfarsa G; Azizi G; Anvari E; Baradaran B; Jadidi-Niaragh F
J Cell Physiol; 2019 May; 234(5):5478-5487. PubMed ID: 30417346
[TBL] [Abstract][Full Text] [Related]
19. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
20. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage.
Nicol SM; Bray SE; Black HD; Lorimore SA; Wright EG; Lane DP; Meek DW; Coates PJ; Fuller-Pace FV
Oncogene; 2013 Jul; 32(29):3461-9. PubMed ID: 22986526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
